Skip to content

Evaluation of clinical efficacy and experimental study on the treatment of ulcerative colitis by Quyushengxin Formula

Evaluation of clinical efficacy and experimental study on the treatment of ulcerative colitis by Quyushengxin Formula

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082454
Enrollment
Unknown
Registered
2024-03-29
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

Control Group:Mesalazine enteric-coated tablets (Sarfo, manufactured by Losan Pharma GmbH, Germany, 0.5 g/tablet) are to be taken orally, 1 tablet each time, 3 times daily. The course of treatment is
Experimental Group:Mesalazine enteric-coated tablets+ Oral administration of Quyushengxin Formula granules, entrusted to Jiangyin Tianjiang Pharmaceutical Co., Ltd. to produce, 1 pack per time, 3 tim

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? It meets the diagnostic criteria of mildly or moderately active ulcerative colitis; ? Chinese medicine diagnosis is damp-heat in the intestines; ? Age =18 years and =75 years, gender is not limited; ? Voluntarily participate in this clinical trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: ? Combination of cardiovascular and cerebrovascular diseases, hepatic and renal insufficiency, hematopoietic system and other serious basic diseases; ? Combined with bacterial dysentery, intestinal obstruction, intestinal perforation, intestinal tumors, multiple polyps in the colon, and so on; ? Combined mental illnesses that cannot cooperate with the treatment; ? Pregnant or preparing for pregnancy, breastfeeding women; ? Those who are allergic or hypersensitive to the components of the study drug; ? Patients who are using glucocorticoids, immunosuppressants or biological agents; ? Patients who have participated in other clinical studies within the last 3 months.

Design outcomes

Primary

MeasureTime frame
Clinical remission rate;

Secondary

MeasureTime frame
Chinese Medicine Symptom Score;MDA;SOD;Improved Baron scores;Quality of life assessment;Incidence of adverse reactions;

Countries

China

Contacts

Public ContactWang Zhenyi

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

drxinhuo@163.com+86 136 0176 0317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026